Search company, investor...

Calistoga Pharmaceuticals

Founded Year



Acquired | Acquired

Total Raised




About Calistoga Pharmaceuticals

Calistoga Pharmaceuticals is a biopharmaceutical company developing multiple compounds selectively targeting the PI3K pathway, a pathway known to be involved in certain cancers and inflammatory diseases.In February 2011, Calistoga Pharmaceuticals was acquired by Gilead Sciences. The valuation of Calistoga Pharmaceuticals was $375 million.

Headquarters Location

2101 - 4th Avenue Suite 1960

Seattle, Washington, 98121,

United States


Missing: Calistoga Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Calistoga Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Calistoga Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Calistoga Pharmaceuticals is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Latest Calistoga Pharmaceuticals News

Big Pharma backers jump on board 'Treg' cartographer's lead round with up to six candidates in the pipe

Jun 22, 2021

Kyle Blankenship Managing Editor Among the wealth of emerg­ing tar­gets in on­col­o­gy, im­mune sys­tem sup­press­ing reg­u­la­to­ry T cells — bet­ter known as “Tregs” — have earned some big-name in­ter­est in re­cent years. Now, a West Coast start­up bet­ter map­ping Tregs in hu­man tis­sue has scored a slate of Big Phar­ma back­ers to dri­ve its grow­ing pipeline in­to the clin­ic. South San Fran­cis­co-based TRexBio emerged from stealth Tues­day with a $57 mil­lion Se­ries A and the back­ing of in­vest­ment funds from Big Phar­ma gi­ants Eli Lil­ly, J&J and Pfiz­er, the biotech said in a re­lease. Car­ol Gal­lagher TRex’s plat­form maps the bi­ol­o­gy and func­tion of hu­man tis­sue Tregs to iden­ti­fy tar­gets in on­col­o­gy and au­toim­mune dis­or­ders. The com­pa­ny’s “deep bi­ol­o­gy” plat­forms pro­duce high-res­o­lu­tion pro­fil­ing of hu­man tis­sues to cre­ate “tis­sue-like” Tregs, the com­pa­ny said. The biotech says it has six pre­clin­i­cal can­di­dates cur­rent­ly in its pipeline and is on pace to name its two lead drugs with­in the next year. TRex’s plat­form has iden­ti­fied 20 nov­el tar­gets so far, it said. The biotech will be led by Chair­man Car­ol Gal­lagher, the for­mer CEO of Cal­is­to­ga Phar­ma­ceu­ti­cals and a part­ner at New En­ter­prise As­so­ci­ates for the last sev­en years, and John­ston Er­win, a 36-year Lil­ly vet­er­an who will take the role of CEO. Er­win most re­cent­ly worked as VP of cor­po­rate busi­ness de­vel­op­ment. “The com­pa­ny has a sig­nif­i­cant foun­da­tion in place, with a com­pelling vi­sion, ded­i­cat­ed team and ro­bust sci­ence,” Er­win said in a state­ment. “I am ex­cit­ed to lead the com­pa­ny in­to its next stage of de­vel­op­ment and ul­ti­mate­ly trans­form the lives of pa­tients by bring­ing a new gen­er­a­tion of im­mune-based ther­a­pies to the world.” Ovid Tri­fan Mean­while, TRex’s clin­i­cal pro­gram will be led by Ovid Tri­fan, most re­cent­ly CMO and VP of de­vel­op­ment at Apex­i­gen. Pri­or to that, Tri­fan held se­nior roles in clin­i­cal re­search at Bris­tol My­ers Squibb and J&J, fo­cus­ing on the on­col­o­gy space. Tri­fan will gear up to bring TRex’s lead pro­grams in­to the clin­ic by the end of the year. The found­ing team is al­so joined by CSO Melanie Klein­schek, who will dri­ve the boat on TRex’s dis­cov­ery plat­form. Tap­ping in­to im­muno­sup­pres­sant reg­u­la­to­ry T cells, which con­trol the pro­lif­er­a­tion of cy­tokines and T cells to main­tain what’s called tis­sue home­osta­sis, has seen a wealth of in­ter­est in re­cent years as com­pa­nies look to tamp down over­ac­tive im­mune sys­tems. Melanie Klein­schek In Feb­ru­ary, Mer­ck signed away $1.85 bil­lion to ac­quire Pan­dion Phar­ma­ceu­ti­cals and its pipeline of drugs tar­get­ing Tregs for au­toim­mune con­di­tions with the lead com­pound look­ing to bind with IL-2. That lead drug, dubbed PT101, will go af­ter ul­cer­a­tive col­i­tis and scored a win in a Phase Ia tri­al ear­li­er this year. In that 56-pa­tient study, PT101 in­creased Treg lev­els by 260% and in­creased the lev­el of high CD25-ex­press­ing Tregs, known as CD25 bright Tregs, by a whop­ping 6,250%, Pan­dion said. The drug al­so hits its marks on safe­ty and tol­er­a­bil­i­ty. On a much small­er scale, No­var­tis and RA Cap­i­tal backed a $20 mil­lion seed round back in Au­gust for a com­pa­ny called Gen­tiBio, which is al­so look­ing to de­vel­op Treg can­di­dates. But those cer­tain­ly aren’t the on­ly two play­ers in that race. AUTHOR The transgenic cows are going public. SAB Biotherapeutics, the Sioux Falls, SD company trying to extract antibody treatments from genetically modified cows, announced Tuesday they would merge with the life science-focused SPAC Big Cypress Acquisition Corp. The deal will value the company at $325 million and equip them with $118 million. That’s pennies next to some of the other biotechs to go public with SPACs in the past year: Valo Health , valued at $2.8 billion, or 23andMe , valued at $3.5 billion. But it’s a significant leap for SAB, a company that previously relied on government grants and modest venture rounds as they focused on infectious diseases — a field long overlooked by VCs and pharma prior to Covid-19. Keep reading Endpoints with a free subscription Unlock this story instantly and join 109,800+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Amber Tong Senior Editor It wasn’t easy navigating the manufacturing and controls issues that had led the FDA to reject ViiV Healthcare’s first pitch for the once-monthly HIV regimen cabotegravir and rilpivirine. But even as Kimberly Smith was knee-deep in sorting out those problems and putting together a new package that finally won the regulators over this January, her business development team kept looking for things that would take them to the next level. Keep reading Endpoints with a free subscription Unlock this story instantly and join 109,800+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Max Gelman Editor If you take Alex Zhavoronkov at his word, it won’t be long until he rules over biotech’s AI drug discovery arena from atop his perch as Insilico CEO. On the heels of a megaround announced Tuesday morning, the media-savvy exec outlined a vision of the not-so-distant future where AI-focused companies crash and burn akin to the dot-com bubble in the early 2000s. Zhavoronkov likened the current environment to 1998, when there was a glut of biotechs that soaked up capital but proved unable to deliver on their promises, he opined to Endpoints News. Read More Amber Tong Senior Editor As Emma Walmsley reveals details this Wednesday about the upcoming split of GlaxoSmithKline’s pharma and consumer units, some tough questions may be coming her way. Elliott Management, the activist investor that’s previously threatened an attack on GSK (but eventually backed off ), is floating more radical changes like replacing the CEO, further breaking up the company and spinning out the vaccine unit, or reviewing the focus on cancer drugs, the Financial Times reported . Keep reading Endpoints with a free subscription Unlock this story instantly and join 109,800+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Zachary Brennan Senior Editor A coalition of employers and health care purchasers are calling on the top House and Senate leaders to take a hard look at the “astronomical price” of Biogen’s new Alzheimer’s drug Aduhelm and “move boldly” to enact prescription drug pricing reform. The group EmployersRx, which includes the American Benefits Council and the National Alliance of Healthcare Purchaser Coalitions among others, says that while it strongly supports market solutions to establish reasonable prices, when no market exists — as is the case for aducanumab — “we support allowing the federal government to enter into meaningful negotiations on the price of drugs on behalf of all payers.” Read More

Calistoga Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Calistoga Pharmaceuticals founded?

    Calistoga Pharmaceuticals was founded in 2006.

  • Where is Calistoga Pharmaceuticals's headquarters?

    Calistoga Pharmaceuticals's headquarters is located at 2101 - 4th Avenue, Seattle.

  • What is Calistoga Pharmaceuticals's latest funding round?

    Calistoga Pharmaceuticals's latest funding round is Acquired.

  • How much did Calistoga Pharmaceuticals raise?

    Calistoga Pharmaceuticals raised a total of $96.2M.

  • Who are the investors of Calistoga Pharmaceuticals?

    Investors of Calistoga Pharmaceuticals include Gilead Sciences, Frazier Healthcare Partners, Alta Partners, Three Arch Partners, Amgen Ventures and 4 more.

  • Who are Calistoga Pharmaceuticals's competitors?

    Competitors of Calistoga Pharmaceuticals include Arena Pharmaceuticals, Constellation Pharmaceuticals, Tetraphase Pharmaceuticals, Ardelyx, Intercept Pharmaceuticals and 13 more.

Compare Calistoga Pharmaceuticals to Competitors

Alvine Pharmaceuticals

Alvine Pharmaceuticals is a clinical-stage, specialty biopharmaceutical company focused on the development of biologics targeting autoimmune and inflammatory diseases, including celiac disease. Alvine is focusing clinical development efforts on ALV003, an investigational drug in phase 2 trials that could potentially be the first approved therapeutic treatment for patients with celiac disease. ALV003 is an orally administered mixture of two recombinant gluten-specific proteases, a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP). ALV003 targets gluten and degrades it into small fragments, which, in vitro, diminishes its immunogenicity. ALV003 is being developed as a potential treatment for celiac disease patients in conjunction with a gluten-free diet and is currently in phase 2 clinical development.

Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Locus Pharmaceuticals

Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing small molecule therapeutic drugs to address unmet medical needs. The company's core technology is a fragment-based, computational approach, which Locus has combinated with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.